SCHEMBL21240537

SCHEMBL21240537

COc1cc(OC)c(Cl)c(-c2cc3cnc(SC)nc3c(N3CCC3)n2)c1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TP53 P04637 1/20 0.35
▸ PDE4B Q07343 4/20 0.35
▸ PDE4A P27815 2/20 0.35
▸ PDE4C Q08493 2/20 0.35
▸ PDE4D Q08499 2/20 0.35
▸ PDE11A Q9HCR9 2/20 0.35
▸ PDE3B Q13370 1/20 0.35
▸ FGFR4 P22455 5/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ FGFR1 P11362 5/20 0.33
▸ FGFR2 P21802 1/20 0.32
▸ FGFR3 P22607 1/20 0.32
▸ ADORA3 P0DMS8 1/20 0.31
▸ ADORA2A P29274 1/20 0.31
▸ CHRNB2 P17787 1/20 0.31
▸ CHRNA4 P43681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29578158 1.00 NOS1 (0.36) NOS1MEN1KMT2ATP53PDE4B
SCHEMBL30045100 0.98 NOS1 (0.38) NOS1MEN1KMT2ATP53PDE4B
SCHEMBL20331789 0.98 NOS1 (0.38) NOS1MEN1KMT2ATP53PDE4B
SCHEMBL20331796 0.97 NOS1 (0.40) NOS1MEN1KMT2ATP53PDE4B
SCHEMBL20331101 0.94 MEN1 (0.36) NOS1MEN1KMT2ATP53PDE4B
SCHEMBL20331483 0.91 PDE4B (0.45) NOS1KMT2APDE4BPDE4APDE4C
SCHEMBL29578278 0.91 PDE4B (0.45) NOS1KMT2APDE4BPDE4APDE4C
SCHEMBL21252147 0.91 MEN1 (0.36) NOS1MEN1KMT2ATP53PDE4B
SCHEMBL20331794 0.89 PDE4B (0.35) NOS1MEN1KMT2ATP53PDE4B
SCHEMBL21240427 0.89 SUV39H2 (0.36) TP53PDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-01-17 — — US disclosed
EP-3524603-B1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2022-06-08 — — EP disclosed
US-10968220-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-04-06 — — US disclosed
US-10968220-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-04-06 — — US disclosed
US-20190270742-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2019-09-05 — — US disclosed
US-20190270742-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2019-09-05 — — US disclosed
EP-3524603-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2019-08-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270742-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FGFR4, FGFR2, FGFR1 NOS1 3504/4885MEN1 745/4885KMT2A 2964/4885
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof FGFR4, FGFR2, FGFR1 NOS1 3504/4885MEN1 745/4885KMT2A 2964/4885
US-10968220-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof FGFR4, FGFR2, FGFR1 NOS1 3504/4885MEN1 745/4885KMT2A 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback